Sutro Biopharma, Inc. · NASDAQ:STRO

Sutro Biopharma — Investor Presentation (March 2024)

30 slides from Sutro Biopharma's investor presentation, March 2024

  1. Slide 1: Company Overview

    Company Overview March 2024 Sutro Biopharma NASDAQ: STRO

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state

  3. Slide 3: Sutro is a Clinical-Stage Oncology Company Focused on Designing and Developing Precise Biologics

    Sutro is a Clinical-Stage Oncology Company Focused on Designing and Developing Precise Biologics, Including ADCs, to Achieve a Wider Therapeutic Window to Benefit More Patients Luveltamab tazevibulin Innovative Development Toolkit Phase 1 data has demonstrated Assets optimized for purity and efficac

  4. Slide 4: Sutro's Robust Pipeline of Product Candidates

    Sutro’s Robust Pipeline of Product Candidates Demonstrates our Innovative Processes and Designed Intentionally to Expand Patient Benefit in Areas of High Unmet Need WORLDWIDE OR PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2/3 GEOGRAPHIC PARTNER SUTRO-LED PROGRAMS Ovaria

  5. Slide 5: Achievements and Milestones

    Achievements and Milestones Targeted Timing Luveltamab tazevibulin (luvelta, STRO-002) in Multiple Indications Highlight potential multi-cancer opportunity for luvelta in comprehensive presentation January 2024 ✓ LPI for Part 1 of REFRaME-O1, a Phase 2/3 registration-directed trial in platinum-resis

  6. Slide 6: Luveltamab Tazevibulin – A Pipeline in a Drug

    Luveltamab Tazevibulin – A Pipeline in a Drug (Luvelta, STRO-002)

  7. Slide 7: Luvelta: Exemplifies Sutro's Innovation in ADC Development

    Luvelta: Exemplifies Sutro’s Innovation in ADC Development Next-Generation ADCs Cell-free XpressCF® Luvelta FolRα-targeting ADC: A Have the Potential to Improve Proven Technology and Pipeline-in-a-Drug Opportunity Clinical Outcomes and Partnership Model Combinability • Promising clinical activity ha

  8. Slide 8: Luvelta: Potential for Significant Commercial Opportunities

    Luvelta: Potential for Significant Commercial Opportunities, Initially in Ovarian Cancer and Expanding to Additional FolRα Expressing Cancers Luvelta Potentially Doubles the Estimated Annual Incidence in FolRα-Expressing Patient Populations Addressable PROC Patients (U.S., Europe and Japan) Percent

  9. Slide 9: Luvelta: Strategic Development Plan Aimed at Realizing the Full Potential

    Luvelta: Strategic Development Plan Aimed at Realizing the Full Potential Therapeutic Area Preclinical Phase 1/1B Phase 2/3 2024 Milestones • Part 1: LPI – 1H REFRαME-O1 Registration-directed Trial • Part 2: Open EU Sites– 2H Dose Escalation Complete Phase 1 program Ovarian Dose Expansion supported

  10. Slide 10: Luvelta: Peds RAM-AML Strategically Positioned for Potential PRV

    Luvelta: Peds RAM-AML Strategically Positioned for Potential PRV and Accelerates Market Entry and Commercial Readiness for OC Eligibility Dose Finding Dose Expansion Key Endpoints • Relapsed/Refractory N = 3-6 • Complete remission (CR) 3.5 mg/kg rate CBFA2T3::GLIS2 AML IV q2w Lead in Dose • ≥ 5% Bon

  11. Slide 11: Luvelta Demonstrated the Ability to Treat 8 out of 10 Women with Ovarian Cancer

    Luvelta Demonstrated the Ability to Treat 8 out of 10 Women with Ovarian Cancer Due to FolRα expression ≥25% Treatment Eligibility is Driven Comparison of Potential Luvelta Population by FolRα Biomarker Test with Approved ADC Population Luvelta has demonstrated clinical activity in PROC TPS Staining

  12. Slide 12: Luvelta Registrational Strategy Supported by Clinical Data from ~100 Treated Patients

    Luvelta Registrational Strategy Supported by Clinical Data from ~100 Treated Patients Across all Doses Maximum Reduction in Tumor Target Lesions in RECIST-Evaluable Patients (N=92 Evaluable) 20% 3 in 5.2, 2 in 4.3, 2 in <=2.9, and 1 in >=5.6mg/kg -30% Partial response Ovarian Cancer Patients Total (

  13. Slide 13: Luvelta Demonstrated Compelling Anti-Tumor Activity and Tolerable Safety in Ovarian Cancer

    Luvelta Demonstrated Compelling Anti-Tumor Activity and Tolerable Safety Broadly in Ovarian Cancer Phase 1: Phase 1: Dose Escalation Dose Expansion Escalation Combo w/ Bevacizumab Signal Seeking Plus G-CSF (Neutropenia Mgt) N = 39 N = 18 N = 44 N = 16 Reduced high-grade Optimal dose range Tolerable

  14. Slide 14: Luvelta Monotherapy Safety Profile Manageable with Low Discontinuation Rate

    Luvelta Monotherapy Safety Profile has been Manageable with Low Discontinuation Rate due to Neutropenia TEAEs (N=99) Neutropenia Preferred Term All Grade Grade 3+ • Primarily uncomplicated (febrile neutropenia < 5%) Incidence ≥35% Patients reporting at least one event 99 (100.0%) 86 (86.9%) • Well m

  15. Slide 15: Luvelta: Anti-Tumor Activity in Lower and/or Variable FolRα Expression Tumors

    Luvelta: Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile In Lower and/or Variable FolRα Expression Tumors Additional Indications Endometrial RAM AML1 NSCLC N = 17 N = 25 Preclinical Evidence of anti-tumor activity Meaningful clinical responses, including complete Single dos

  16. Slide 16: Prophylactic G-CSF Demonstrated Effective Reduction of Neutropenia

    Use of Prophylactic G-CSF on Day 8 with 5.2mg/kg Dose Demonstrated Effective Reduction of Neutropenia Maximum Reduction in Tumor Grade 3+ Neutropenia Cohort A1 vs. Cohort with G-CSF2 Target Lesions (N=16) 20% Cycle 1 Cycle 1+2 100% 80% 71.4% 66.7% Percent Patients 60% 73.7% -30% 90.6% Reduction Redu

  17. Slide 17: Luvelta Showed Anti-tumor Activity in FolRα Expressing Endometrial Cancer

    Luvelta Showed Evidence of Anti-tumor Activity in FolRα Expressing Endometrial Cancer: Data Presented at ESMO 2023 Maximum Reduction in Target Lesions* Consistent Safety Signals Observed TPS (%) 5 15 1 2 99 6 25 45 15 35 8 45 75 18 70 30 Total (N = 17) TEAEs, n (%) Most Common Events Any grade* Grad

  18. Slide 18: Luvelta Showed Anti-Tumor Activity in Pediatric RAM Phenotype AML

    Luvelta Showed Anti-Tumor Activity in Pediatric RAM Phenotype AML: Data Highlighted at ASH 2023 Received Luvelta as Non-Fractionated Dosing Regimen Safety Overview (N=21*^) 1.0 censored Total (N = 21) TEAES occurring in ≥25% of patients 0.8 who received monotherapy with Luvelta *Luvelta EAP Any grad

  19. Slide 19: FolRα is Broadly Expressed Across Multiple Indications

    19 mRNA expression level (RMA, log2) 4 6 8 10 12 endometrium (27) ovary (51) kidney (34) bile duct (8) colorectal (61) breast (58) pancreas (44) stomach (38) esophagus (25) lung_NSC (131) other (15) upper_aerodigestive (32) urinary tract (27) chondrosarcoma (4) glioma (62) liver (28) medulloblastoma

  20. Slide 20: STRO-003 and Emerging Research Portfolio

    STRO-003 and Emerging Research Portfolio

  21. Slide 21: Sutro's Flexibility in Design and Innovative Toolkit

    Sutro’s Flexibility in Design and Innovative Toolkit Provide the Potential for Superior Solutions and the Opportunity for an Improved Patient Experience Conjugated Antibody MODALITY ADC / ISAC iADC / ADC2 Bispecific ADC TARGET Dual 1. Mono- or Bispecific TAA Targeting Tumor Tumor Tumor Antigen Antig

  22. Slide 22: Express Cell-free Platform: Established, Scalable & Reproducible Manufacturing

    Express Cell-free Platform: Established, Scalable & Reproducible Manufacturing Approach / Feature Advantages Results • Stockpiled cell-free extract used to create a Cell-free extract and platform wide variety of proteins elements produced separately from proteins • Eliminates cell line development a

  23. Slide 23: Limitless Innovation: Sutro's Approach to Future ADC Development

    Limitless Innovation: Sutro’s Approach to Future ADC Development On-target Activity Improve- ments ADC Immunogenic Resistance Potency Cell Death Induction to Top1/Exatecan Dual Conjugate * DAR > 8* *Unique advantage of non-natural amino acid incorporation by Cell-free XpressCF® 23 NON-CONFIDENTIAL

  24. Slide 24: STRO-003: A Novel ROR1 Targeted ADC is Designed for Purpose

    STRO 003 STRO-003: A Novel ROR1 Targeted ADC is Designed for Purpose ROR1 biology makes it an Expansive indication Potential for attractive clinical attractive ADC target space in oncology performance ROR1: Role in cancer progression Clinical validation of ROR1 in Low copy number and and expressed i

  25. Slide 25: STRO-003 Is a Novel, Conjugation Site-Optimized ROR1 ADC

    STRO 003 Sutro’s Innovative Design: STRO-003 Is a Novel, Conjugation Site-Optimized ROR1 ADC Eight Topoisomerase-1 Inhibitors per mAb Coupled With β-Glucuronidase Cleavable Linkers STRO-003 is a single homogeneous ADC with a drug- 1 antibody ratio (DAR) of 8, targeting ROR1 tumor antigen ROR1 1 Targ

  26. Slide 26: STRO-003 Demonstrated Anti-Tumor Activity in Nonclinical NSCLC and Breast Cancer Models

    STRO 003 STRO 03 Demonstrated Anti-Tumor Activity in Nonclinical NSCLC and Breast Cancer Models Nonclinical models of anti-tumor activity across low and heterogenous ROR1 antigen levels Tumor Growth ROR1 Expression 3000 • STRO-003 demonstrated complete regression of human patient-derived Tumor size

  27. Slide 27: STRO-003 Well Tolerated in Preclinical Toxicity Models

    STRO 003 STRO 03 Well Tolerated in Preclinical Toxicity Models at High Dose Levels—Potentially Reducing Lung Toxicity While Demonstrating ROR1-dependent In Vitro Tumor Killing NTERA-2 (ROR1+++) MCF-7 (ROR1-) 120 120 Relative cell viability (%) Relative cell viability (%) 100 100 80 80 60 60 • STRO-0

  28. Slide 28: New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC)

    New Modality for Cold Tumors: Immunostimulatory Antibody Drug Conjugate (iADC) Featuring dual drug conjugation technology with both cytotoxin and immune modulator Strategic iADC Collaboration Initiated on June 27, 2022 • $90M upfront to develop iADCs for up to three targets • Research activities are

  29. Slide 29: Financial Overview – December 31, 2023

    Financial Overview – December 31, 2023 Well-capitalized through multiple funding sources ~$375M (1) Projected cash runway into in cash, cash equivalents & 2H 2025, marketable securities based on current business plans and and Vaxcyte stock assumptions ~0.7M shares Funding generated from our collabor

  30. Slide 30: Experienced Leadership Team

    Experienced Leadership Team William Newell, JD Anne Borgman, MD Ed Albini, MBA Hans-Peter Gerber, PhD Chief Executive Officer and Chief Medical Officer Chief Financial Officer Chief Scientific Officer Member of the Board of Directors Jane Chung, RPh Linda Fitzpatrick Nicki Vasquez, PhD Venkatesh Sri

Sutro Biopharma — Investor Presentation (March 2024) on 6ix